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Both animal and clinical studies have demonstrated that omega-3 fatty acids have
anti-arrhythmic properties. It has been suggested that these anti-arrhythmic effects are
due to modulation of the activity of various myocardial calcium handling proteins such as
ryanodine receptor (RyR), L-type calcium current and sodium/calcium exchanger. In this
article, we review all the data available on the effects of omega-3 fatty acids on ventricular
myocardial calcium handling. In addition we highlight some unanswered questions and
discuss possible therapeutic benefits of omega-3 fatty acids.
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INTRODUCTION
Omega-3 poly-unsaturated fatty acids (PUFA) have generated
considerable interest as well as controversy regarding their role as
anti-arrhythmic agents. A number of observational studies have
shown that consumption of fish leads to a reduction in incidence
of sudden deaths (Burr et al., 1989; Siscovick et al., 1995). The
GISSI–Prevenzione trial, an open-label design trial found that
1 g/day of n-3 PUFA [(containing 289mg of Eicosapentaenoic
acid (EPA) and 577mg Docosahexaenoic acid (DHA)] led to
a 20% Relative Risk Reduction (RRR, 95% CI 6–23%) in total
mortality after only 3 months of treatment without a signif-
icant change in myocardial infarction or stroke (1999). This
suggested that the beneficial effects of PUFA are mainly related to
an anti-arrhythmic action that prevents life-threatening arrhyth-
mias. This generated a great deal of interest in the potential of
PUFA as anti-arrhythmic agents and 3 prominent randomized,
double blind, placebo controlled trials have been conducted (Leaf
et al., 2005; Raitt et al., 2005; Brouwer et al., 2006). These trials
analyzed the effects of PUFA on time to appropriate therapy for
ventricular arrhythmias in ICD patients. They failed to demon-
strate a convincing anti-arrhythmic effect and ignited the debate
on whether PUFA have anti-arrhythmic properties. It has been
suggested that the lack of efficacy of PUFA in patients with ICDs is
due to the fact that this population contains patients with various
Abbreviations: PUFA, Poly-Unsaturated Fatty Acids; EPA, Eicosapentaenoic
acid; DHA, Docosahexaenoic acid; ICD, Internal cardioverter-defibrillator; DAD,
delayed afer-depolarization; TA, triggered activity; AP, action potential; SR, sar-
coplasmic reticulum; RyR, ryanodine receptor; SERCA, Sarcoplasmic reticulum Ca
ATPase; ATP, adenosine triphosphate; NCX, Na+/Ca2+ exchanger; SCR, sponta-
neous calcium release; VT, ventricular tachycardia; EAD, early after-depolarization;
VF, ventricular fibrillation.
arrhythmia mechanisms while the main anti-arrhythmic actions
of PUFA are due to modulation of calcium handling leading to
prevention of delayed after-depolarization (DAD) and triggered
activity (TA) (Den Ruijter and Coronel, 2009). PUFA have also
been demonstrated to diversely modulate a variety of cardiac ion
channels (inhibit sodium, calcium and potassium currents other
than IKS and IK1) as reviewed in detail in (Moreno et al., 2012)
and hence the electrophysiological effects depend on the underly-
ing cardiac pathology, setting of the arrhythmia and the method
of application of PUFA. In this article we review the experimental
evidence supporting the notion that the anti-arrhythmic actions
of PUFA are due to modulation of myocardial calcium handling
as well as prevention of DADs and TA. Whilst a variety of studies
have also failed to reach a consensus on the effects of PUFA on
the atrial myocardium, this review shall only focus on the effects
of PUFA on calcium handling in the ventricular myocardium. To
introduce the subject, we rapidly summarize normal myocardial
calcium handling and the alteration in calcium handling that lead
to DADs and TA.
MYOCARDIAL CALCIUM HANDLING
In cardiacmuscle, cytosolic calcium levels control the level of acti-
vation of the contractile proteins, the myofilaments and therefore
the onset duration and intensity of contraction. The electri-
cal activation with the spreading of the action potential (AP)
throughout the heart initiates contraction by causing a transient
increase in cytosolic calcium concentration, the systolic calcium
transient (Bers, 2002). The AP generates the systolic calcium tran-
sient via a process called calcium-induced calcium release. During
this process, the influx of a small amount of calcium via the sar-
colemmal L-type calcium channels that are activated by the AP,
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activates the sarcoplasmic reticulum (SR) calcium release chan-
nel, the ryanodine receptor (RyR), and triggers the release of
calcium from the SR. Relaxation occurs after 100–200ms when
calcium gradually decays back to diastolic levels. This decline in
cytosolic calcium concentration is due to termination of calcium
release from the SR (inactivation of RyR) and rapid removal of
calcium from the cytosol. Two systems are responsible for cal-
cium removal from the SR—the sarcoplasmic reticulum calcium
ATPase (SERCA) that uses ATP as energy to pump calcium back
into the SR and the Na+/Ca2+ exchanger (NCX) that exchanges
the efflux of one Ca2+ (2 positive charges) with the influx of three
Na+ (3 positive charges). The activation of NCX leads to a net
influx of a positive charge and therefore a net inward current. The
above process is shown in Figure 1A.
MODULATION OF CA HANDLING
The amplitude of the calcium transient determines the level of
activation of the myofilaments and therefore the intensity of con-
traction and it is finely modulated. The two main factors that
determine the amount of calcium released from the SR and the
amplitude of the calcium transient are: the amplitude of the
L-type calcium current (Trafford et al., 2001) and the calcium
FIGURE 1 | Myocardial Calcium handling. (A) Normal Ca handling: The AP
(1) activates the L-type calcium channels, the influx of a small amount of
calcium via these channels (2) activates the RyR and triggers the release of a
greater amount of calcium from the SR in to the cytosol (3). Calcium activates
the myofilaments that generate contraction. During relaxation calcium is
rapidly removed from the cytosol by SERCA (5) that pumps calcium back into
the SR and by NCX that couples the efflux of 1 Ca2+ (two positive charges) to
the influx of 3 Na+ (three positive charges) and generates an inward current.
(B) Generation of SCR and DADs: When intra SR calcium concentration is
very high the SR can release calcium (1) independently from an AP this
process is called spontaneous calcium release (SCR). This calcium activates
the NCX (2) that generates an inward current and produces a delayed
after—depolarization (DAD). The record on the left shows simultaneous
recording of membrane potential and cytosolic calcium levels. The AP is
triggers the calcium transient (CaT) while during diastole a SCR triggers a
DAD.
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concentration in the SR (Shannon et al., 2000). The SR Ca con-
centration can be increased by stimulation of SERCA activity
and prolongation of the duration of the AP and decreased by
stimulation of NCX activity.
In vivo the main modulator of the calcium transient amplitude
is β adrenergic stimulation that via cAMP-mediated activation
of protein kinase A stimulates both the L-type calcium channel
and SERCA. This leads to an increase in L-type calcium current
and SR Ca content and therefore a substantial increase in calcium
transient amplitude (Hussain and Orchard, 1997).
ARRHYTHMIAS RELATED TO Ca HANDLING
Release of calcium from the SR can also occur independently
from an AP during diastole (Venetucci et al., 2008). This pro-
cess is called spontaneous calcium release (SCR) and occurs when
the SR calcium concentration reaches a crucial threshold level
(Diaz et al., 1997). In addition recently Belevych et al. (2012) ele-
gantly demonstrated that soon after a systolic calcium transient
the RyRs enter a refractory state and calcium wave occur only
once the RyR have recovered from this refractory state even if the
SR threshold is reached. Therefore the two conditions necessary
for the generation of SCR are: (1) Increased SR Ca content up to
the SR threshold for SCR (2) Recovery of RyR from refractory
state. SCR activates the NCX that generates an inward current
and a DAD. When a DAD reaches the threshold for activation
of the Na channels, it initiates an AP which in turn causes TA
and arrhythmias. The process of SCR and generation of DADs
is shown in Figure 1B. SCR, DAD, and TA are responsible for
the onset of arrhythmias in various clinical settings including
digitalis-induced arrhythmias, some forms of heart failure and
catecholaminergic polymorphic VT (a genetic arrhythmia syn-
drome caused by mutations of the RyR and CASQ2 genes). The
scheme illustrated above suggests that there are two main thera-
peutic strategies that can be used to prevent the onset of calcium
handling related arrhythmias: prevention of the onset of an SCR
and prevention of triggering of an AP by a DAD. In view of the
fact that the generation of DAD through SCR has been shown
to be dependent on threshold SR calcium content (Diaz et al.,
1997; Trafford et al., 2000; Jiang et al., 2005), the first strat-
egy can be achieved by preventing the SR calcium content from
reaching the threshold for SCR either by decreasing SR calcium
content (Venetucci et al., 2007; Llach et al., 2011) or by rais-
ing SR threshold for SCR via inhibition of RyR (Venetucci et al.,
2006; Maxwell et al., 2012). The second strategy can be achieved
via inhibition of sodium channels that reduces the number of
sodium channels ready to be activated when a DAD occurs and
therefore reduces the likelihood that the DAD will initiate and AP
and cause TA. Whilst this strategy can be beneficial in preventing
arrhythmias caused by TA such as in heart failure, it could also be
pro-arrhythmic during acute ischaemia by facilitating re-entry. In
the following section, we will illustrate the experimental evidence
that suggests that PUFA prevent SCR, DADs and TA via some of
the mechanisms described.
EFFECTS OF PUFA ON MYOCARDIAL CALCIUM HANDLING
The effects of PUFA on calcium handling by cardiac myocytes
have been extensively studied and an interesting picture has
emerged. The effects vary depending on the modality of admin-
istration; two different modalities of application have been used:
(1) application of free unesterified PUFA in external bath solu-
tion, (2) chronic diet supplementation that leads to incorporation
in cardiac membrane as esters. To simplify, we will describe these
effects separately.
EFFECTS OF FREE PUFA ON MYOCARDIAL CALCIUM
HANDLING (ALSO SUMMARISED IN TABLE 1)
Application of free PUFA has profound effects on calcium han-
dling. Macleod et al studied the effects of free PUFA on sodium
and calcium currents and AP (Macleod et al., 1998). Both in rat as
well as guinea pig isolated cardiac myocytes, free PUFA produced
a dose-dependent reduction in sodium and calcium currents.
The effects on AP duration were different in the two species. In
rat ventricular myocytes, concentrations of EPA or DHA up to
7.5μM caused AP prolongation. At concentrations above 10μM
AP shortening was observed. In guinea-pigs however AP shorten-
ing was observed at lower concentrations such as around 5μM.
In a second paper the same authors (Rodrigo et al., 1999) also
demonstrated that PUFA at the same concentrations inhibit RyR.
The inhibition of calcium current and the RyR and the shortening
of the AP produce marked reduction in calcium transient ampli-
tude and cell shortening. Stephen O’Neill’s group studied in detail
the effects of PUFA on Ca handling in rat ventricular myocytes
(Negretti et al., 2000; O’Neill et al., 2002). They first studied the
effects of EPA and DHA on RyR and confirmed that PUFA inhibit
RyR and also increase the SR threshold for SCR (Negretti et al.,
2000). In the same paper, they also demonstrated that free PUFA
have no effects on NCX. In a follow-on paper (Szentandrássy
et al., 2007), they also analyzed the effects of EPA on L-type
calcium current, SERCA function and calcium transient. As pre-
viously described by Rodrigo et al. EPA reduces calcium current
amplitude (Rodrigo et al., 1999). Interestingly EPA also increased
SERCA activity by promoting phosphorylation of phospholam-
ban. The characterization of the calcium transient demonstrated
that 5μM EPA reduced calcium transient if the myocytes were
stimulated using voltage-clamp and increased it if the cell was
stimulated using current-clamp. During current-clamp the cells
are allowed to express their AP and the application of EPA (via
inhibition of the transient outward current) produces a substan-
tial prolongation of the AP. This increases SR calcium content
substantially and therefore increases calcium transient amplitude
despite inhibition of the L-type calcium current. During voltage
clamp the cell is not allowed to express its AP. The membrane
potential is controlled and the cell is stimulated using a 100ms
membrane potential step. The application of EPA does not pro-
duce any change in membrane potential and therefore does not
produce a significant increase in SR Ca content. EPA still reduces
calcium current amplitude and this reduction cause a significant
reduction in calcium transient amplitude.
Free PUFA have also been shown to reduce the response to
adrenergic stimulation. In 1995 Kang and Leaf (1995) demon-
strated that the application of free PUFA to spontaneously beating
rat neonatal myocytes attenuated the response to isoprenaline.
PUFA reduced the increase in beating frequency produced by iso-
prenaline and prevented the onset of contracture. More recently,
www.frontiersin.org October 2012 | Volume 3 | Article 373 | 3
Sankaranarayanan and Venetucci Anti-arrhythmic effects of PUFA and calcium handling
Table 1 | Summarising effects of free PUFA on myocardial calcium handling.
Authors Species studied Findings
Macleod et al., 1998 Rat and guinea pig isolated cardiac
myocytes
1. Dose dependant reduction in sodium and calcium currents
2. Rat - or DHA up to 7.5μM caused AP prolongation
Guinea pig—AP shortening was observed already at lower
concentrations such as around 5μM
Rodrigo et al., 1999 Rat and guinea pig isolated cardiac
myocytes
Inhibition of calcium current and the RyR and the shortening of the AP
produce marked reduction in calcium transient amplitude and cell
shortening
Negretti et al., 2000 and
O’Neill et al., 2002
Rat ventricular myocytes 1. PUFA inhibit RyR and also increase the SR threshold for SCR
2. Free PUFA have no effects on NCX
Szentandrássy et al., 2007 Rat ventricular myocytes 1. EPA reduces calcium current amplitude
2. EPA also increased SERCA activity by promoting phosphorylation of
phospholamban
3. The characterization of the calcium transient demonstrated that 5μM
EPA reduced calcium transient if the myocytes were stimulated using
voltage-clamp and increased it if the cell was stimulated using
current-clamp
EFFECTS ON ADRENERGIC STIMULATION
Kang and Leaf, 1995 Rat neonatal myocytes Application of free PUFA to spontaneously beating rat neonatal
myocytes attenuated the response to isoprenaline, reduced the
increase in beating frequency produced by isoprenaline and prevented
the onset of contracture
Den Ruijter et al., 2008 Rabbit and human myocytes In rabbit myocytes, free PUFA reduced amplitude of the calcium
transient and attenuated the increase in calcium transient amplitude
produced by noradrenaline. In addition, in the presence of PUFA
noradrenaline did not prolong the AP and failed to induce EADs and
DADs.
Similar effects were detected during experiments on human cardiac
myocytes derived from severe congestive cardiac failure hearts
explanted during cardiac transplantation.
Szentandrássy et al., 2007 Rat ventricular myocytes PUFA reduce cAMP levels but directly stimulate PKA
Den Ruijter et al. (2008) characterized the effects of PUFA on
the adrenergic response in rabbit and humanmyocytes (shown in
Figure 2). In rabbit myocytes, free PUFA reduced the amplitude
of the calcium transient and attenuated the increase in calcium
transient amplitude produced by noradrenaline. In addition, in
the presence of PUFA noradrenaline did not prolong the AP and
failed to induce EADs and DADs. Similar effects were detected
during experiments on human cardiac myocytes derived from
severe congestive cardiac failure hearts explanted during cardiac
transplantation. The mechanisms responsible for the attenuation
in adrenergic response are not fully understood. Szentandrássy
et al. (2007) demonstrated that PUFA reduce cAMP levels but
directly stimulate PKA. It is conceivable that during adrenergic
stimulation PUFA significantly attenuate the increase in cAMP
levels and therefore attenuate the response to adrenergic stimu-
lation. In summary, these studies have consistently demonstrated
that free PUFA in vitro exert profound effects on calciumhandling
at baseline and after adrenergic stimulation. These effects involve
several components of the calcium handling system and produce
marked reduction in calcium transient amplitude. These studies
also suggest that free PUFA prevent DADs in vitro both by raising
SR threshold for calcium waves (through inhibition of RyR) and
by reducing the SR calcium content both before and after adren-
ergic stimulation. In addition, they inhibit sodium current and
therefore prevent TA. It is unclear whether these effects also occur
in vivo (see later).
EFFECTS OF MEMBRANE INCORPORATED PUFA
As mentioned above, dietary supplementation with EPA and
DHA leads to their incorporation in the cardiac membrane
phospholipids. Several studies have investigated the effects of
incorporated PUFA but have reached conflicting reports. To sim-
plify the subject we illustrate separately the effects of incorporated
PUFA on calcium handling at baseline and following adrenergic
stimulation.
EFFECTS ON CALCIUM HANDLING AT BASELINE
In 2001 Leifert et al. (2001) gave a DHA and EPA enriched diet
to adult rats for 3 weeks. This diet increased the levels of incor-
poration of DHA (from 6 to 20% of total phospholipids) and
EPA (from 0 to 3.2%). The incorporated PUFA did not affect
calcium transient amplitude but decreased its rate of decay. In
addition, incorporation of PUFA did not affect SR Ca content.
The authors suggested that the reduction in calcium transient
rate of decay was due to reduced NCX-mediated removal in the
PUFA group. It is likely that the effects are more complex because
isolated reduction of NCX function would have also increased
SR calcium content. The Coronel group studied the effects of
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FIGURE 2 | PUFA reduce the sensitivity to noradrenalin. (A) Effects of
free Oleic acid (OA), free EPA and free DHA on AP duration before and after
application of noradrenalin. (B) Mean data for AP duration. ∗P < 0.05
indicates statistical differences with or without noradrenalin. (C) Effects of
free OA free EPA and free DHA on calcium transient before and after
application of noradrenalin. (D) Mean data for diastolic calcium levels.
∗P < 0.05 indicates statistical differences between DHA or EPA and control.
(E) Mean data for peak systolic calcium levels. #P < 0.05 indicates statistical
differences between DHA or EPA and OA. Picture reproduced with
permission from Den Ruijter et al. Circulation (2008) 117, 536–544.
a PUFA-enriched diet on pig ventricular myocytes. The diets
were given for 8 weeks and produced a significant increase in
the levels of incorporated DHA (from not detectable to around
7%) and EPA (from not detectable to around 15%). The most
striking effect of incorporated PUFA was reduction in AP dura-
tion which was more prominent at slow frequencies and was
mainly due to increase in two repolarizing currents: the slow
component of the delayed rectifier current and inward recti-
fier K current (Den Ruijter et al., 2006; Verkerk et al., 2006).
The analysis of calcium handling showed that the incorporated
PUFA did not produce a significant effect on calcium transient
amplitude but accelerated its rate of decay. SR calcium con-
tent was not affected but both L-type calcium current amplitude
and NCX function were significantly reduced. The acceleration
of the calcium transient rate of decay is probably explained by
the shorter AP duration, but what is surprising is the fact that
despite reduction in L-type calcium current amplitude, the cal-
cium transient amplitude itself was not affected. Recently Billman
et al. (2010) assessed the effects of DHA and EPA supplements
(Omacor 1–2 or 4 tablets a day) on contractility and calcium tran-
sient in mixed breed dogs. The tablets were given for 3 months.
The supplements produced a significant increase in EPA and
DHA incorporation levels in cardiac membranes. However, the
increased incorporation levels did not produce any significant
effect on cardiac contractility, calcium transient amplitude and
on L-type calcium current amplitude.
EFFECTS ON RESPONSE TO ADRENERGIC STIMULATION
Leifert et al. (2001) reported that incorporation of DHA and EPA
in membranes of rat ventricular myocytes reduced the incidence
of calcium waves and DADs during challenge with the β agonist
isoproterenol. From the data illustrated by the authors, it is
difficult to understand the mechanisms responsible for these pro-
tective effects. The authors also showed that the incorporation of
DHA and EPA does not affect the increase in calcium transient
amplitude produced by isoproterenol. Similarly to what described
at baseline there was a reduction in the rate of decay of the cal-
cium transient that was significant only at 0.2Hz. From these
data is difficult to establish how incorporated PUFA reduced
the incidence of calcium waves. It is not clear whether PUFA
affected SR threshold for calcium waves and/or SR calcium con-
tent. Similar to what was previously described by Leifert et al.
in rat cardiac myocytes, the Coronel group demonstrated that
incorporation of DHA and EPA in the membrane of pig ventricu-
lar myocytes reduced the incidence of calcium waves and DADs
during challenge with norepinephrine (Berecki et al., 2007).
They investigated in detail the mechanism responsible for these
effects and demonstrated that membrane incorporation of PUFA
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reduces the response to norepinephrine. In particular, incorpo-
rated PUFA blunted the increase in SR calcium content produced
by norepinephrine and therefore attenuated the increase in cal-
cium transient produced by norepinephrine. Incorporated PUFA
also prevented the prolongation of AP potential produced by
norepinephrine and it is unclear whether the blunting in the
increase of SR calcium content is simply due to the effects on AP
duration or also involves blunting of the stimulation of SERCA
activity. In a recent paper, Billman et al. showed that incorpora-
tion of DHA and EPA in cardiac membranes of dogs did not affect
the response to isoproterenol. The authors however did not inves-
tigate whether incorporated PUFA prevented the onset of calcium
waves and DADs. However the finding that they do not attenuate
response to isoproterenol would suggest that in these experiments
they would not prevent DADs. An important issue that was not
investigated by all these studies is whether incorporated PUFA
have any effect on RyR and affect the threshold for SCR. Some
studies inferred that because calcium transient amplitude was not
affected there was no effect on RyR.
In summary, the studies that have investigated the effects of
incorporated PUFA on Ca handling have reached conflicting con-
clusions. The cause of these differences remains unclear. Billman
et al. have suggested that they may be related to the different
species utilized in the studies. More specifically pigs (utilized by
the Coronel Group) have a calcium-dependent transient outward
current that is absent in dog and human myocytes. This could
cause different effects of incorporated PUFA on AP duration and
therefore SR calcium content before and after adrenergic stimula-
tion. However this does not explain the differences in the effects
of incorporated PUFA on the L-type Ca current. In addition, the
pig study that documented attenuated adrenergic response used
norepinephrine (β1 and α1 agonist) to produce adrenergic stimu-
lation while the other two studies that documented limited effects
utilized isoproterenol (β1and β2 agonist). This raises the possi-
bility that stimulation with norepinephrine is more susceptible to
modulation by incorporated PUFA. This is a possibility that needs
to be investigated.
COMBINED EFFECTS OF FREE AND MEMBRANE
INCORPORATED PUFA
One issue that has not been addressed by the studies performed
is whether incorporation of PUFA in cardiac membrane affects
the response to free PUFA. The issue is particularly important
because diet supplementation leads both to membrane incorpo-
ration and to an increase in free circulating PUFA. Only one study
has tried to address this issue (Den Ruijter et al., 2010) and has
demonstrated that incorporation of PUFA in the membrane of
rabbit myocytes shortens AP but prevents any further shorten-
ing when free PUFA are applied. Unfortunately this study has not
determined whether the effects of free PUFA on calcium handling
(inhibition of RyR and L-type calcium current) are affected by
incorporated PUFA.enl.
DO THE EFFECTS OF PUFA ON CALCIUM HANDLING DETECTED
In vitro OCCUR In vivo AS WELL?
The large amount of experimental evidence gained with in vitro
experiments has not been supported by in vivo experiments.
Several studies have demonstrated that in vivo both infu-
sion of PUFA (free PUFA) (Billman et al., 1999) and chronic
dietary supplementation (that leads to membrane incorporation
and increased circulating free PUFA) protect from ischaemia-
reperfusion related arrhythmias (McLennan et al., 1988; London
et al., 2007). However a recent study evaluating the effects of
dietary n-3 PUFA on susceptibility to post-myocardial infarction
ventricular fibrillation in dogs, showed that despite significant
increases in circulating as well as left ventricular PUFA lev-
els, PUFA not only failed to prevent ischaemia-induced VF.
Contrary to expectations dietary PUFA exerted pro-arrhythmic
effects facilitating the onset of VF both in non-infarcted ani-
mals and in low-risk post-MI dogs that did not have VF prior
to initiation of PUFA diet (Billman et al., 2012). These conflict-
ing results highlight the fact that the pathogenesis of ischaemia
reperfusion related arrhythmias is complex and certainly does
not involve just alterations in calcium handling (Janse and Wit,
1989). Therefore this experimental evidence cannot be used as
proof that PUFA modulate calcium handling in vivo. The evi-
dence that PUFA in vivo modulate myocardial calcium handling
is limited. This question could be answered by studies on car-
diac contractility and on calcium handling related arrhythmias.
To date no study has assessed the effects of acute PUFA adminis-
tration on cardiac function and the two studies that have assessed
the effects of PUFA diet supplementation on cardiac function
have not confirmed the in vitro findings. In 1992, McLennan et al.
(1992) demonstrated that dietary supplementation with PUFA in
marmosets increased ejection fraction by enhancing LV filling.
Recently Billman et al. (2010) studied the effects of PUFA supple-
mentation on LV function (assessed by echo) and demonstrated
that despite significant increases in the incorporation of DHA and
EPA in the cardiac membrane (and probably in circulating free
PUFA) there was no change in LV function. Interestingly these
results are very different from what one would expect on the basis
of in vitro studies that point more towards a reduction in calcium
transient amplitude, cardiac contractility and LV function. These
data suggest that in vivo there are complex modulating factors
that mitigate or abolish the effects of PUFA observed in vitro. The
evidence that PUFA prevent arrhythmias which are exclusively
due to abnormalities in calcium handling, calcium waves and
DADs (such as catecholaminergic and digoxin-related arrhyth-
mias) is also limited. Only one study (Gudbjarnason et al., 1989)
demonstrated that in rats a PUFA diet prevented the onset of
VF following isoproterenol infusion. There is clearly a need for
more targeted studies that specifically assess the anti-arrhythmic
potential of PUFA in arrhythmia syndromes caused exclusively
by abnormalities in calcium handling. To this purpose, a study
in animal models and or patients with CPVT would address
this point.
CONCLUSIONS
A large body of evidence gained from cellular experiments sup-
ports the idea that PUFA modulate myocardial calcium handling
and exert anti-arrhythmic effect by preventing SCR and DADs.
This large body of in vitro evidence still awaits confirmation by
in vivo animal studies and clinical studies. Over the next decade
targeted studies will tell us whether all these in vitro findings
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also occur in vivo and whether PUFA are a treatment strategy for
calcium handling related arrhythmias.
FUNDING
Dr. Sankaranarayanan’s research is funded by a grant from the
British Heart Foundation (Grant Reference FS/11/15/28693).
Dr. Venetucci’s research is funded by a grant from the British
Heart Foundation (Grant Reference FS/10/63/28374).
ACKNOWLEDGMENTS
We would like to dedicate this paper to the memory of our
dear friend and colleague Dr Stephen O’ Neill who unfor-
tunately passed away prematurely. His elegant experiments
contributed substantially to our understanding of cardiomy-
ocyte calcium handling as well as its relationship to fish oils.
We thank Dr Lisa Redfern for her careful reading of the
manuscript.
REFERENCES
Belevych, A. E., Terentyev, D.,
Terentyeva, R., Ho, H. T.,
Gyorke, I., Bonilla, I. M., et al.
(2012). Shortened Ca2+ signaling
refractoriness underlies cellular
arrhythmogenesis in a postinfarc-
tion model of sudden cardiac death
Circ. Res. 110, 569–577.
Berecki, G., Den Ruijter, H. M.,
Verkerk, A. O., Schumacher, C. A.,
Baartscheer, A., Bakker, D., et al.
(2007). Dietary fish oil reduces the
incidence of triggered arrhythmias
in pig ventricular myocytes. Heart
Rhythm 4, 1452–1460.
Bers, D. M. (2002). Cardiac excitation-
contraction coupling. Nature 415,
198–205.
Billman, G. E., Harris, W. S., Carnes,
C. A., Adamson, P. B., Vanoli, E.,
and Schwartz, P. J. (2012). Dietary
omega-3 fatty acids and suscep-
tibility to ventricular fibrillation:
lack of protection and a proar-
rhythmic effect. Circ. Arrhythm.
Electrophysiol. 5, 553–560.
Billman, G. E., Kang, J. X., and Leaf,
A. (1999). Prevention of sudden car-
diac death by dietary pure omega-3
polyunsaturated fatty acids in dogs.
Circulation 99, 2452–2457.
Billman, G. E., Nishijima, Y., Belevych,
A. E., Terentyev, D., Xu, Y., Haizlip,
K. M., et al. (2010). Effects of
dietary omega-3 fatty acids on
ventricular function in dogs with
healed myocardial infarctions:
in vivo and in vitro studies. Am.
J. Physiol. Heart Circ. Physiol. 298,
H1219–H1228.
Brouwer, I. A., Zock, P. L., Camm,
A. J., Bocker, D., Hauer, R. N.,
Wever, E. F., et al. (2006). Effect of
fish oil on ventricular tachyarrhyth-
mia and death in patients with
implantable cardioverter defibrilla-
tors: the Study on Omega-3 Fatty
Acids and Ventricular Arrhythmia
(SOFA) randomized trial. JAMA
295, 2613–2619.
Burr, M. L., Fehily, A. M., Gilbert,
J. F., Rogers, S., Holliday, R. M.,
Sweetnam, P. M., et al. (1989).
Effects of changes in fat, fish,
and fibre intakes on death and
myocardial reinfarction: diet and
reinfarction trial (DART). Lancet 2,
757–761.
Den Ruijter, H. M., Berecki, G.,
Verkerk, A. O., Bakker, D.,
Baartscheer, A., Schumacher,
C. A., et al. (2008). Acute adminis-
tration of fish oil inhibits triggered
activity in isolated myocytes from
rabbits and patients with heart
failure. Circulation 117, 536–544.
Den Ruijter, H. M., and Coronel, R.
(2009). The response to fish oil in
patients with heart disease depends
on the predominant arrhythmia
mechanism. Cardiovasc. Drugs Ther.
23, 333–334.
Den Ruijter, H. M., Verkerk, A.
O., Berecki, G., Bakker, D., van
Ginneken, A. C., and Coronel, R.
(2006). Dietary fish oil reduces the
occurrence of early afterdepolariza-
tions in pig ventricular myocytes.
J. Mol. Cell Cardiol. 41, 914–917.
Den Ruijter, H. M., Verkerk, A.
O., and Coronel, R. (2010).
Incorporated fish oil fatty acids
prevent action potential shortening
induced by circulating fish oil fatty
acids. Front. Physiol. 1:149. doi:
10.3389/fphys.2010.00149
Diaz, M. E., Trafford, A. W., O’Neill,
S. C., and Eisner, D. A. (1997).
Measurement of sarcoplasmic retic-
ulum Ca2+ content and sarcolem-
mal Ca2+ fluxes in isolated rat
ventricular myocytes during spon-
taneous Ca2+ release. J. Physiol.
501(Pt 1), 3–16.
Dietary supplementation with n-
3 polyunsaturated fatty acids
and vitamin E after myocardial
infarction: results of the GISSI-
Prevenzione trial. Gruppo Italiano
per lo Studio della Sopravvivenza
nell’Infarto miocardico. (1999).
Lancet 354, 447–455.
Gudbjarnason, S., Benediktsdottir, V.
E., and Skuladottir, G. (1989).
Effects of n-3 polyunsaturated fatty
acids on coronary heart disease.
Bibl. Nutr. Dieta 43, 1–12.
Hussain, M., and Orchard, C. H.
(1997). Sarcoplasmic reticulum
Ca2+ content, L-type Ca2+ current
and the Ca2+ transient in rat
myocytes during beta-adrenergic
stimulation. J. Physiol. 505(Pt 2),
385–402.
Janse, M. J., and Wit, A. L. (1989).
Electrophysiological mechanisms
of ventricular arrhythmias result-
ing from myocardial ischemia
and infarction. Physiol. Rev. 69,
1049–1169.
Jiang, D., Wang, R., Xiao, B., Kong, H.,
Hunt, D. J., Choi, P., et al. (2005).
Enhanced store overload-induced
Ca2+ release and channel sensitiv-
ity to luminal Ca2+ activation are
common defects of RyR2 muta-
tions linked to ventricular tachycar-
dia and sudden death. Circ. Res. 97,
1173–1181.
Kang, J. X., and Leaf, A. (1995).
Prevention and termination of
beta-adrenergic agonist-induced
arrhythmias by free polyunsatu-
rated fatty acids in neonatal rat
cardiac myocytes. Biochem. Biophys.
Res. Commun. 208, 629–636.
Leaf, A., Albert, C. M., Josephson, M.,
Steinhaus, D., Kluger, J., Kang, J.
X., et al. (2005). Prevention of fatal
arrhythmias in high-risk subjects
by fish oil n-3 fatty acid intake.
Circulation 112, 2762–2768.
Leifert, W. R., Dorian, C. L., Jahangiri,
A., and McMurchie, E. J. (2001).
Dietary fish oil prevents asyn-
chronous contractility and alters
Ca(2+) handling in adult rat car-
diomyocytes. J. Nutr. Biochem. 12,
365–376.
Llach, A., Molina, C. E., varez-
Lacalle, E., Tort, L., Benitez, R.,
and Hove-Madsen, L. (2011).
Detection, properties, and
frequency of local calcium
release from the sarcoplasmic
reticulum in teleost cardiomy-
ocytes. PLoS ONE 6:e23708. doi:
10.1371/journal.pone.0023708
London, B., Albert, C., Anderson, M.
E., Giles, W. R., Van Wagoner, D. R.,
Balk, E., et al. (2007). Omega-3 fatty
acids and cardiac arrhythmias: prior
studies and recommendations for
future research: a report from the
National Heart, Lung, and Blood
Institute and Office Of Dietary
Supplements Omega-3 Fatty
Acids and their Role in Cardiac
Arrhythmogenesis Workshop.
Circulation 116, e320–e335.
Macleod, J. C., Macknight, A. D., and
Rodrigo, G. C. (1998). The elec-
trical and mechanical response of
adult guinea pig and rat ventricu-
lar myocytes to omega3 polyunsat-
urated fatty acids. Eur. J. Pharmacol.
356, 261–270.
Maxwell, J. T., Domeier, T. L., and
Blatter, L. A. (2012). Dantrolene
prevents arrhythmogenic Ca2+
release in heart failure. Am. J.
Physiol. Heart Circ. Physiol. 302,
H953–H963.
McLennan, P. L., Abeywardena, M.
Y., and Charnock, J. S. (1988).
Dietary fish oil prevents ven-
tricular fibrillation following
coronary artery occlusion and
reperfusion. Am. Heart J. 116,
709–717.
McLennan, P. L., Barnden, L. R., Bridle,
T. M., Abeywardena, M. Y., and
Charnock, J. S. (1992). Dietary fat
modulation of left ventricular ejec-
tion fraction in themarmoset due to
enhanced filling.Cardiovasc. Res. 26,
871–877.
Moreno, C., Macias, A., Prieto, A.,
de la Cru, A., Gonzalez, T., and
Valenzuela, C. (2012). Effects
of n-3 polyunsaturated fatty
acids on cardiac ion channels.
Front. Physiol. 3: 00245. doi:
10.3389/fphys.2012.00245
Negretti, N., Perez, M. R., Walker, D.,
and O’Neill, S. C. (2000). Inhibition
of sarcoplasmic reticulum func-
tion by polyunsaturated fatty acids
in intact, isolated myocytes from
rat ventricular muscle. J. Physiol.
523(Pt 2), 367–375.
O’Neill, S. C., Perez, M. R., Hammond,
K. E., Sheader, E. A., and Negretti,
N. (2002). Direct and indirect mod-
ulation of rat cardiac sarcoplasmic
reticulum function by n-3 polyun-
saturated fatty acids. J. Physiol. 538,
179–184.
Raitt, M. H., Connor, W. E., Morris, C.,
Kron, J., Halperin, B., Chugh,
S. S., et al. (2005). Fish oil
supplementation and risk of
ventricular tachycardia and
www.frontiersin.org October 2012 | Volume 3 | Article 373 | 7
Sankaranarayanan and Venetucci Anti-arrhythmic effects of PUFA and calcium handling
ventricular fibrillation in patients
with implantable defibrillators: a
randomized controlled trial. JAMA
293, 2884–2891.
Rodrigo, G. C., Dhanapala, S., and
Macknight, A. D. (1999). Effects
of eicosapentaenoic acid on the
contraction of intact, and spon-
taneous contraction of chemically
permeabilized mammalian ventric-
ular myocytes. J. Mol. Cell. Cardiol.
31, 733–743.
Shannon, T. R., Ginsburg, K. S., and
Bers, D. M. (2000). Potentiation
of fractional sarcoplasmic reticulum
calcium release by total and free
intra-sarcoplasmic reticulum cal-
cium concentration. Biophys. J. 78,
334–343.
Siscovick, D. S., Raghunathan, T. E.,
King, I., Weinmann, S., Wicklund,
K. G., Albright, J., et al. (1995).
Dietary intake and cell membrane
levels of long-chain n-3 polyunsat-
urated fatty acids and the risk of
primary cardiac arrest. JAMA 274,
1363–1367.
Szentandrássy, N., Perez-Bido, M.
R., Alonzo, E., Negretti, N., and
O’Neill, S. C. (2007). Protein kinase
A is activated by the n-3 polyunsat-
urated fatty acid eicosapentaenoic
acid in rat ventricular muscle. J.
Physiol. 582, 349–358.
Trafford, A. W., Diaz, M. E., and Eisner,
D. A. (2001). Coordinated control
of cell Ca(2+) loading and trig-
gered release from the sarcoplas-
mic reticulum underlies the rapid
inotropic response to increased L-
type Ca(2+) current. Circ. Res. 88,
195–201.
Trafford, A. W., Sibbring, G. C., Diaz,
M. E., and Eisner, D. A. (2000).
The effects of low concentrations of
caffeine on spontaneous Ca release
in isolated rat ventricular myocytes.
Cell Calcium 28, 269–276.
Venetucci, L. A., Trafford, A. W.,
Diaz, M. E., O’Neill, S. C., and
Eisner, D. A. (2006). Reducing ryan-
odine receptor open probability as
a means to abolish spontaneous
Ca2+ release and increase Ca2+
transient amplitude in adult ven-
tricular myocytes. Circ. Res. 98,
1299–1305.
Venetucci, L. A., Trafford, A. W., and
Eisner, D. A. (2007). Increasing
ryanodine receptor open probability
alone does not produce arrhythmo-
genic calcium waves: threshold sar-
coplasmic reticulum calcium con-
tent is required. Circ. Res. 100,
105–111.
Venetucci, L. A., Trafford, A. W.,
O’Neill, S. C., and Eisner, D. A.
(2008). The sarcoplasmic reticu-
lum and arrhythmogenic calcium
release.Cardiovasc. Res. 77, 285–292.
Verkerk, A. O., van Ginneken, A. C.,
Berecki, G., Den Ruijter, H. M.,
Schumacher, C. A., Veldkamp, M.
W., et al. (2006). Incorporated sar-
colemmal fish oil fatty acids shorten
pig ventricular action potentials.
Cardiovasc. Res. 70, 509–520.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 21 June 2012; paper pend-
ing published: 03 July 2012; accepted:
30 August 2012; published online: 01
October 2012.
Citation: Sankaranarayanan R and
Venetucci L (2012) Are the anti-
arrhythmic effects of omega-3 fatty
acids due to modulation of myocardial
calcium handling? Front. Physio. 3:373.
doi: 10.3389/fphys.2012.00373
This article was submitted to Frontiers in
Cardiac Electrophysiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Sankaranarayanan
and Venetucci. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
Frontiers in Physiology | Cardiac Electrophysiology October 2012 | Volume 3 | Article 373 | 8
